The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)
October 2, 2019. For decades, the brand-name drug industry has relentlessly promoted the message that any reduction in its government-protected monopolies would have detrimental effects on innovation. Members of Congress on both sides of the aisle have taken that message to heart, largely leaving pharmaceutical monopolies alone as drug prices have skyrocketed.
GENEVA – 26 June 2019 – The International Generic and Biosimilar medicines Association (IGBA) today released a revised report Trade Principles: Generic and Biosimilar Medicines which addresses how trade agreements can be designed to foster trade in generic and biosimilar medicines and improve access to affordable medicines.
- Committing to Global Health: Balancing Access and Sustainability key to success
- IGBA congratulates health Canada for decision on biologics naming that supports growing global consensus
- Statement on the Passing of Dilip Shah
- Suzette Kox nominated as Secretary General of the International Generic and Biosimilar medicines Association